In December 2025, CMS announced the BALANCE Model — Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth. The name is bureaucratic. The design choice behind it is not.
The model enables Medicare Part D plans and state Medicaid agencies to cover GLP-1 medications for weight management. What makes it notable isn't just the expanded access — it's that CMS is pairing GLP-1 coverage with evidence-based lifestyle supports as part of the model's structure.
CMS is launching the program in Medicaid as early as May 2026, with Medicare Part D following in January 2027. Separately, a short-term Medicare GLP-1 Bridge program begins in July 2026, covering Wegovy and Zepbound at a $50 monthly copay for eligible beneficiaries and providing early access while BALANCE ramps up.
Why This Matters Beyond Medicare
The BALANCE Model is a Medicare and Medicaid program. Self-funded employers aren't directly affected by it. But the design signal it sends is worth paying attention to.
The model is based on what CMS describes as "emerging evidence that combines access to GLP-1 medications with access to evidence-based lifestyle supports to achieve better long-term health outcomes." Under BALANCE, CMS negotiates directly with manufacturers, and the negotiation areas include not just pricing and coverage criteria, but also evidence-based lifestyle support offerings. The CMS Innovation Center will evaluate the model's impact on costs, adherence, outcomes, and beneficiary experience.
The model's design suggests CMS is taking seriously the question that the GLP-1 durability data has raised: whether medication access alone produces the long-term outcomes that justify sustained spending at scale.
For employer plans, that concern should sound familiar. The Oxford BMJ meta-analysis (West et al., 2026) found that weight regain after stopping GLP-1s was roughly four times faster than after behavioral interventions. The Peterson-KFF employer focus groups found that large employers are already pulling back GLP-1 coverage as costs climb without clear durability. The pattern is consistent: medication works, but medication as a standalone model has a durability problem.
CMS appears to be designing around that same problem — and that's a meaningful signal for anyone thinking about GLP-1 benefits design.
What the BALANCE Model Looks Like in Practice
The model has three components worth understanding:
Negotiated pricing. CMS negotiates directly with GLP-1 manufacturers for lower net prices and standardized coverage terms. This addresses the cost side of the equation — something self-funded employers are trying to manage through PBM negotiations and formulary design.
Coverage criteria. The model establishes eligibility requirements tied to provider attestation of qualifying conditions. Participation is voluntary for manufacturers, states, and Part D plans. The specifics of coverage criteria may evolve as more details are released — employers should watch the final terms closely as a reference point for their own plan design.
Lifestyle support. This is the component most relevant to the durability conversation. CMS includes evidence-based lifestyle support offerings as part of the negotiated coverage package. Beneficiaries receiving GLP-1s through BALANCE will have access to a lifestyle support program. The model is explicitly designed to test whether pairing medication with lifestyle intervention produces better outcomes and cost sustainability than medication access alone.
What This Suggests for Employer Benefits Design
Self-funded employers don't need to wait for CMS to tell them what the data already suggests. But the BALANCE Model offers a useful framework to consider:
Pair GLP-1 coverage with lifestyle and behavioral support. If CMS is designing Medicare coverage to include lifestyle intervention alongside GLP-1 access, employers should consider whether their own plans treat medication as a standalone benefit. Programs that help employees understand how their bodies respond to dietary choices — and build sustainable habits around that awareness — address the durability gap that pharmacotherapy alone leaves open.
Think about plan design holistically. The BALANCE Model's approach of combining drug access with behavioral support isn't just a cost play — it's a clinical design choice grounded in evidence about what produces lasting outcomes. Employers building their own GLP-1 benefit strategies can apply the same logic: design for durability, not just access.
Measure durability, not just utilization. CMS is evaluating the BALANCE Model on adherence, outcomes, and cost sustainability — not just whether beneficiaries fill prescriptions. Employers should apply the same lens: are employees maintaining weight loss? Are metabolic health markers improving over time? Is the total cost of care decreasing, or are you funding a recurring cycle?
What to Watch
The BALANCE Model is voluntary for manufacturers, states, and plans. Its success depends on participation rates and how robustly the lifestyle components are designed and delivered. CMS has said it will release more details on state and Part D plan participation throughout 2026.
The more immediate development is the Medicare GLP-1 Bridge launching in July 2026. At $50/month for eligible beneficiaries, it will expand GLP-1 access in the Medicare population. How that affects utilization trends, employer benchmarking, and the broader cost conversation is worth tracking closely.
The larger signal is in the model design itself. CMS is testing whether drug access paired with lifestyle support produces better, more cost-effective outcomes than drug access alone. For employers wrestling with the same question in their own benefits plans, the BALANCE Model is worth watching — not as a mandate, but as a framework that reflects where the evidence is pointing.
